Atossa Genetics Inc. (NASDAQ:ATOS) announced that a preliminary analysis from its recently completed Phase 2 study of the company’s proprietary 20mg daily topical Z Endoxifen (“Endoxifen”) showed significant and rapid reduction in mammographic breast density (MBD). Studies by others using tamoxifen have demonstrated that density reduction induced by tamoxifen is associated with a significant reduction in breast cancer incidence.
Technical Stock Analysis
Atossa Genetics Inc. (NASDAQ:ATOS), a Healthcare sector firm, traded 276792 shares in last trading session and stock decreased -3.46% with closing price of $2.23 per share. Company gross margins represents its total sales revenue minus its cost of goods sold (COGS), divided by the total sales revenue earned by the company, expressed as a percentage. And its good to know that the higher that percentage, the more the company retains on each dollar of sales, to service its other costs and the debt obligations.
Investment Worthy Stock or not?
For personal guess ROI is usually expressed as a percentage and is typically used for taking any financial decisions, for the purpose of comparing a Atossa Genetics Inc. (NASDAQ:ATOS)’s profitability or to compare the efficiency of different investments.
52-Week Range are valuable stats for watching Atossa Genetics Inc. (NASDAQ:ATOS)’s past year fluctuation as that gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range. Atossa Genetics Inc. (NASDAQ:ATOS)’s stock value has moved between $0.8 – 7.43 in last one year.
Analysts mean target price for Atossa Genetics Inc. (NASDAQ:ATOS) is $9.00.
Its weekly performance is 3.24% while year to date (YTD) performance is 118.63%.
Earnings per share growth is defined as the percentage change in normalised earnings per share over the previous 12 month period to the latest year end. It gives a good picture of the rate at which a company has grown its profitability. Atossa Genetics Inc. (NASDAQ:ATOS)’s EPS growth this year is 49.80%. For best decision making investors should look at Atossa Genetics Inc. (NASDAQ:ATOS)’s EPS growth for next year stands at 20.50%.